ITEMS IN AFP WITH KEYWORD:
May 1, 2019 Issue
Denosumab for Reducing Risk of Fractures in Postmenopausal Women [Medicine by the Numbers]
Denosumab appears to be effective in reducing the risk of vertebral and nonvertebral fractures in postmenopausal women with osteoporosis. Treatment with denosumab does not increase the risk of cancer or death but might increase the risk of infection. However, more studies are required.
It is time to rethink the idea that vaginal atrophy caused by diminished estrogen is the cause of vaginal symptoms associated with menopause. Vaginal estradiol is no more effective than a non-prescription vaginal lubricant or placebo lubricant in the treatment of women with painful intercourse, vagi...
Oct 1, 2018 Issue
Hormone Therapy for Primary Prevention of Cardiovascular Disease in Postmenopausal Women [Medicine by the Numbers]
No benefit was observed in postmenopausal women receiving hormone therapy for primary prevention of cardiovascular disease. Find out more.
Long-term hormone therapy decreased the risk of all fractures, including hip and vertebral fractures. However, the risks far outweighed the benefits of this intervention.
Apr 15, 2018 Issue
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women [Putting Prevention into Practice]
D.M. is a 52-year-old woman who presents to your office for a well-woman visit. She has been menopausal since 50 years of age and has no significant medical or surgical history. She is up to date on her recommended screenings, with normal mammography and colonoscopy results, and has no history of an...
Apr 15, 2018 Issue
Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Women: Recommendation Statement [U.S. Preventive Services Task Force]
The USPSTF recommends against the use of combined estrogen and progestin for the primary prevention of chronic conditions in postmenopausal women and the use of estrogen alone for the primary prevention of chronic conditions in postmenopausal women who have had a hysterectomy.
Transdermal, but not oral, estrogen produced a small improvement in sexual function scores in menopausal women. The increases were very small and may not be noticeable by most women.
Transdermal estrogen plus progestogen, or oral estrogen plus progestogen, is the treatment most likely to effectively reduce the frequency of vasomotor symptoms among menopausal women. Isoflavones and black cohosh were found to be better than placebo.
Hormone therapy is the most effective treatment for the vasomotor symptoms of menopause, although the risks and benefits should be discussed with patients. Patients with genitourinary syndrome of menopause may benefit from vaginal estrogen, nonhormonal vaginal moisturizers, or ospemifene.
Conjugated estrogens/bazedoxifene is effective for the treatment of menopausal symptoms and may be better tolerated than conjugated estrogens/medroxyprogesterone. It will maintain bone mineral density in the lumbar spine and hip, but its effect on fractures is not known. Cardiovascular safety beyond two years is not known.